Adma Biologics reported $124.4M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Adma Biologics USD 124.4M 9.9M Jun/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 147.14M 76.69M Dec/2025
Takeda JPY 1.19T 32.9B Sep/2026